Infectious Disease Control News and Press Releases

Infectious Disease Control

Releases published in the last 30 days.

Page 1 of 1

Skin Prepping Lotion Recalled Due to Microbial Contamination: 12/10/2019 9:38:47 AM; A Florida company recently announced a worldwide recall of 21 lots of skin prepping lotion used for the enhancement of signal quality at electrode sites of healthcare patients.
Immune System Can be Coaxed into Selecting Key Antibodies to Fight HIV: 12/5/2019 5:37:11 PM; Researchers have cleared a major obstacle in the development of an HIV vaccine, proving in animal models that effective, yet short-lasting antibodies can be coaxed into multiplying as a fighting force against the virus.
Gay, bisexual men increasingly agree: HIV “Undetectable Equals Untransmittable”: 12/5/2019 5:14:11 PM; Extensive evidence from HIV prevention research studies has firmly established that “Undetectable Equals Untransmittable,” or U=U. This means that people living with HIV who achieve and maintain an undetectable viral load — the amount of virus in their blood — by taking antiretroviral therapy (ART) as prescribed do not sexually transmit HIV to others.
The 18-Month Listeria Food Outbreak That Started in Canada Has Ended: 12/5/2019 12:23:35 PM; The Canada Food Inspection Agency (CFIA) was the first to issue the food recall warning for cooked, diced chicken that caused the year-and-a-half Listeria outbreak.
Exposure Risks to Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA): 12/2/2019 12:09:39 PM; The first recorded nosocomial outbreak of Methicillin-resistant Staphylococcus aureus (MRSA) in the United States occurred in 1968 in Boston, Massachusetts.
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer: 12/1/2019 7:27:25 PM; AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).
Over 300 children and adolescents die every day from AIDS-related causes: 11/26/2019 7:32:29 PM; The government of Uganda have implemented a number of interventions for children exposed to HIV including point of care for early infant diagnosis of HIV and oral pellets for children living with HIV.
GenapSys Raises $90M Series C Led by Foresite Capital to Commercialize Its Breakthrough Electronic Gene Sequencer: 11/20/2019 1:16:36 PM; GenapSys Inc. announced today that it has completed a $90 million funding round, led by Foresite Capital to commercialize the smallest and most affordable highly accurate sequencer ever developed.
Legionnaires’ disease Outbreak Tied to North Carolina Mountain State Fair: 11/20/2019 11:31:27 AM; The Buncombe County Department of Health and Human Services and the Henderson County Health Department notified the North Carolina Division of Public Health (DPH) on September 23rd of an increase in reported Legionnaires’ disease cases.
Piaggio Fast Forward releases limited edition gita robot with (RED): 11/19/2019 5:02:15 AM; Piaggio Fast Forward, a robotics company revolutionizing active lightweight mobility, announces its partnership with (RED). The limited edition (gita)RED will be available for purchase exclusively during the fifth annual (RED) SHOPATHON, available for sale on Amazon.com/RED and for a limited time.
World’s First AI Health Guidance App in Swahili Launched by Ada Health: 11/19/2019 3:00:50 AM; The first artificial intelligence-based (“AI”) symptom-assessment application to be made available in Swahili has been launched today, unlocking access to health information and advice for more than 100 million people seeking healthcare in East Africa. The app, developed by Ada Health, combines a world-class medical knowledge database with intelligent reasoning technology …
FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions: 11/18/2019 12:46:22 PM; Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab), 1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and …
Histoplasmosis and Fungal Exposure Risks in Homes and Buildings Infested with Bats or Birds: 11/14/2019 10:15:34 AM; Bats living in occupied buildings recently forced employees from a Michigan courthouse, as well as counselors and students from a Florida high school, to relocate due to health concerns associated with their presence.